PT Soho Global Health Tbk, (SOHO) Fair Value & Analysis
Healthcare · ID · Market cap 13.5T IDR
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price −26.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 673.62 IDR – 3,475 IDR · fair‑value band 748.80 IDR – 1,241 IDR · the 1,135 IDR price screens above the 969.59 IDR fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PT Soho Global Health Tbk, (SOHO) currently trades at 1,135 IDR, while our model-based Fair Value estimate is 969.59 IDR — implying the stock looks roughly 14.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, PT Soho Global Health Tbk, generated revenue of 10.7T IDR at a net margin of 6.1%. Revenue declined 1.3% year over year. It earns a return on equity of 23.4%. The balance sheet holds a net cash position of 1.1T IDR. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
PT Soho Global Health Tbk, together with its subsidiaires, operates as a healthcare company in Indonesia. It operates through Distributions, Consumer Health, Alliance, and Others segments. The company researches, develops, and markets specialty-focused medicines for use in the therapeutic areas of immunomodulator, respiratory, inflammation, and liver diseases; offers nonprescription brand products to treat and prevent diseases; and distribution and logistics services. It also offers body defense, stamina and vitality, brain nutrient, eye health, skin care, weight management, and wellness products; sells and markets medical devices and medical equipment products in the areas of wound care, hospital general care, surgery, orthopedics, and in-vitro diagnostics; and provides product registration, marketing intelligence, sales, and marketing support services. In addition, it provides contract manufacturing services for various dosage forms. The company was founded in 1946 and is headquar…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Soho Global Health Tbk, reported revenue of 10.8T IDR in FY2025 versus 7.1T IDR in FY2021, a compound +11.1%/yr. Reported net income was 600B IDR in FY2025, compounding +2.2%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$1,022 | R$1,243 | +22% |
| Cencora, Inc C1CO34 | R$709.32 | R$400.70 | -44% |
| Cardinal Health, Inc CAH | $216.30 | $110.75 | -49% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.7800 | -67% |
| Sitka Gold Corp SIG | A$2.76 | A$0.3300 | -88% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥56.73 | +255% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Soho Global Health Tbk, (SOHO) undervalued?
What is the fair value of SOHO?
What is the quality score of SOHO?
What is the revenue of PT Soho Global Health Tbk, (SOHO)?
What is the net profit margin of SOHO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.